These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 7630926)

  • 1. 5-Hydroxytryptamine pathways in anxiety and its treatment.
    Handley SL
    Pharmacol Ther; 1995 Apr; 66(1):103-48. PubMed ID: 7630926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clarifications on the effects of 5-HT1A agonists and selective 5-HT reuptake inhibitors on the 5-HT system.
    Blier P; de Montigny C
    Neuropsychopharmacology; 1996 Aug; 15(2):213-6. PubMed ID: 8840358
    [No Abstract]   [Full Text] [Related]  

  • 3. The serotonergic system and anxiety.
    Gordon JA; Hen R
    Neuromolecular Med; 2004; 5(1):27-40. PubMed ID: 15001810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin receptors and therapeutics.
    Launay JM; Callebert J; Bondoux D; Loric S; Maroteaux L
    Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):327-36. PubMed ID: 7522716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preface. Physiological, pathophysiological and therapeutic aspects of 5-HT mechanisms.
    Meneses A
    Behav Brain Res; 2008 Dec; 195(1):1. PubMed ID: 18706936
    [No Abstract]   [Full Text] [Related]  

  • 6. [Serotoninergic receptors: physiological and therapeutic implications].
    del Río J; Lasheras B
    Rev Med Univ Navarra; 1993; 38(3):29-38. PubMed ID: 8134752
    [No Abstract]   [Full Text] [Related]  

  • 7. Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents.
    Dubovsky SL
    J Clin Psychiatry; 1994 Feb; 55 Suppl():34-44. PubMed ID: 8077173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs affecting 5-hydroxytryptamine function.
    Drug Ther Bull; 1993 Mar; 31(7):25-7. PubMed ID: 8344147
    [No Abstract]   [Full Text] [Related]  

  • 9. Serotonin dysfunction syndromes: a functional common denominator for classification of depression, anxiety, and obsessive-compulsive disorder.
    Benkert O; Wetzel H; Szegedi A
    Int Clin Psychopharmacol; 1993 Sep; 8 Suppl 1():3-14. PubMed ID: 8254151
    [No Abstract]   [Full Text] [Related]  

  • 10. Serotonergic mechanisms and current and future psychiatric practice.
    Dubovsky SL; Thomas M
    J Clin Psychiatry; 1995; 56 Suppl 2():38-48. PubMed ID: 7844106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of serotonergic agents for treatment of gastrointestinal motility and functional bowel disorders.
    Kindt S; Tack J
    Neurogastroenterol Motil; 2007 Aug; 19 Suppl 2():32-9. PubMed ID: 17620086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of serotonergic function in rat brain by VN2222, a serotonin reuptake inhibitor and 5-HT1A receptor agonist.
    Romero L; Celada P; Martín-Ruiz R; Díaz-Mataix L; Mourelle M; Delgadillo J; Hervás I; Artigas F
    Neuropsychopharmacology; 2003 Mar; 28(3):445-56. PubMed ID: 12629524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders.
    Ressler KJ; Nemeroff CB
    Depress Anxiety; 2000; 12 Suppl 1():2-19. PubMed ID: 11098410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Animal models for studying serotonin (5-HT) receptor subtypes: relationship to 5-HT system pathologies.
    Ogren SO; Misane I
    Nucl Med Biol; 1998 Nov; 25(8):747-9. PubMed ID: 9863561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin in panic disorder and social phobia.
    Sheehan DV; Raj BA; Trehan RR; Knapp EL
    Int Clin Psychopharmacol; 1993 Nov; 8 Suppl 2():63-77. PubMed ID: 7911142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 5-HT2C receptor as a target for mood disorders.
    Serretti A; Artioli P; De Ronchi D
    Expert Opin Ther Targets; 2004 Feb; 8(1):15-23. PubMed ID: 14996615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serotonin syndrome as a result of concomitant use of paroxetine and sumatriptan].
    Hendrix Y; van Zagten MS
    Ned Tijdschr Geneeskd; 2005 Apr; 149(16):888-90. PubMed ID: 15868995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac).
    Ni YG; Miledi R
    Proc Natl Acad Sci U S A; 1997 Mar; 94(5):2036-40. PubMed ID: 9050900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats.
    Jenck F; Moreau JL; Berendsen HH; Boes M; Broekkamp CL; Martin JR; Wichmann J; Van Delft AM
    Eur Neuropsychopharmacol; 1998 Aug; 8(3):161-8. PubMed ID: 9716307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basic advances in serotonin pharmacology.
    Fuller RW
    J Clin Psychiatry; 1992 Oct; 53 Suppl():36-45. PubMed ID: 1429483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.